Shared Resource 09: Leukemia Tissue Bank (LTBSR)

项目总结-白血病组织库共享资源（LTBSR） LTBSR是一个历史悠久的生物库，成立于1997年，采购，加工和储存生物 来自血液病患者的知情同意材料。LTBSR以两种方式获取样本：1）通过 用于未来研究的一般生物库方案;以及2）通过特定的临床研究方案， 收藏需求。LTBSR的主要服务是同意患者，采购样本（例如，血、骨 骨髓和白细胞分离产品），评估样本 质量，向调查人员提供新鲜样本或对其进行储存处理，提供监督程序 使用样本和数据，并将样本和数据交付给经批准的接收方。调查人员收到 沿着临床数据和可用病理学数据（包括 护理标准免疫表型分析和基因测序组）。在本周期，Lapo Alinari博士 (LR)取代了前LTBSR主任（大卫卢卡斯，谁从哥伦布），和博士罗伯特Baiocchi（LR） 取代克拉拉布卢姆菲尔德博士（LR）作为高级学院顾问。LTBSR的具体目标是：1） 同意受试者并从血液病患者中获取样本; 2）统一处理， 使用最先进的程序表征和储存生物样本;以及3）提供生物样本， 相关的临床、病理和基因组数据提供给OSUCCC研究人员和外部机构， 它们可以将来自患者样本的发现与临床或基于人群的结果相关联。比本 在拨款周期内，LTBSR支持了67名研究人员（75%为OSUCCC成员）和所有五名OSUCCC成员 研究项目，45篇出版物（11 > 10影响因子）和19项NCI赠款，包括1项K12，1项K22，1项K23，1项K24，1项K25，1项K26，1项K27，1项K28，1项K29，1项K22，1项K23，1项 P01、13个R 01和2个R35。OSUCCC最近承诺大幅增加样本 通过从淋巴瘤患者的淋巴结取样获得。此外，LTBSR还扩展了以下服务： 从置换手术中收集废弃的正常髋骨作为骨髓基质细胞的来源， 脐带血作为CD 34+造血干细胞的来源。在下一个融资周期，LTBSR将 继续扩大其组织采购服务的广度，解决OSUCCC的研究重点， 免疫肿瘤学、翻译基因组学以及癌症预防和生存。的年度预算 LTBSR是664，631美元，而CCSG的要求是70，451美元。因此，LTBSR利用广泛的机构 只有10.6%的人寻求CCSG基金的支持。

PROJECT SUMMARY – LEUKEMIA TISSUE BANK SHARED RESOURCE (LTBSR) The LTBSR is a longstanding biobank, established in 1997, that procures, processes, and stores biologic material from consenting patients with hematologic diseases. The LTBSR procures samples in two ways: 1) via a general biobanking protocol for future research; and 2) via specific clinical research protocols with special collection needs. The major services of the LTBSR are consenting patients, procuring samples (e.g., blood, bone marrow, and leukapheresis products) as directed by the general or a specific IRB protocol, assessing sample quality, providing fresh samples to investigators or processing them for storage, providing an oversight process for use of samples and data, and delivering samples and data to approved recipients. Investigators receive samples identified phenotypically or genetically, along with clinical data and available pathology data (including standard of care immunophenotyping and genetic sequencing panels). During the current cycle, Dr. Lapo Alinari (LR) replaced the prior LTBSR Director (David Lucas, who moved from Columbus), and Dr. Robert Baiocchi (LR) replaced Dr. Clara Bloomfield (LR) as the Senior Faculty Advisor. The Specific Aims of the LTBSR are to: 1) consent subjects and procure samples from patients with hematologic diseases; 2) uniformly process, characterize and store biospecimens using state-of-the art procedures; and 3) provide biospecimens with associated clinical, pathological and genomic data to OSUCCC researchers and to outside institutions so that they can correlate findings from patient samples with clinical or population-based outcomes. Over the current grant cycle, the LTBSR has supported 67 investigators (75% OSUCCC members) and all five of the OSUCCC research programs, 45 publications (11 > 10 impact factor) and 19 NCI grants, including 1 K12, 1 K22, 1 K23, 1 P01, 13 R01s, and 2 R35s. The OSUCCC has recently made a commitment to substantially increase samples obtained by lymph node sampling from lymphoma patients. In addition, the LTBSR has expanded services for collecting discarded normal hipbone from replacement surgeries as a source of marrow stromal cells and umbilical cord blood as a source of CD34+ hematopoietic stem cells. In the next funding cycle, the LTBSR will continue to expand its breadth of tissue procurement services, addressing the OSUCCC research priorities of immuno-oncology, translational genomics, and cancer prevention and survivorship. The annual budget of the LTBSR is $664,631, yet the CCSG request is $70,451. Thus, the LTBSR leverages extensive institutional support and seeks only 10.6% support from CCSG funds.